Immutep to Present New Data from AIPAC-003 Phase II at 2025 San Antonio Breast Cancer Symposium

Immutep has announced new data from its AIPAC-003 Phase II trial, showing that an immunotherapy-chemotherapy combination of eftilagimod alfa and paclitaxel resulted in strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patients. The trial has also met FDA's Project Optimus requirements and selected 30 mg as the optimal biological dose for eftilagimod alfa. The results will be presented at the 2025 San Antonio Breast Cancer Symposium.